seyhey44, consider this just an alternative input from a very smart person, technology visionary, and accomplished person. Google "why the future doesn't need us" by Bill Joy. The Wired Magazine article is from April 2000, and it will give you some alternative thoughts about the future for those grandchildren. You may not agree with it, but if you have not thought about it, now would be a good time to be exposed to the idea.
cphammer, If the big pharmas really desire to play rough, I think Al could go to Teva and Perrigo who have some proprietary as well as many generic drugs, and they have reach worldwide. It would take some time, but they have the resources, and they would be more than happy with the margins and terms Al Mann may be asking for. In the end assuming Afrezza is FDA approved, the US big pharmas (BP as this board likes to abbreviate) will have to decide if they want to compete and work with MNKD or withdraw.
ariesinapril, I have an acquaintance who subscribed to Cramer's Actions Alerts some years ago. She told me she cancelled when she realized Cramer is more for entertainment value than stock investing. I have never been a subscriber.
kinsma.i6684, what is your native language? In English you use incorrect tenses quite often. You do not spell past tenses of many verbs that end with a final d. You misspell many words, because it seems clear you either do not hear the word's phonetics when it is pronounced correctly, or you simply do not know how to spell the simplest of English words. Since I come across your comments often on this board, I would pay more attention to them if I did not almost immediately recognize they come from a person ignorant of the language in which he is writing.
incel1, heck the "link" is 80 pages. I read five pages of it. We know MNKD stock is being manipulated. How can you write the shorts were never in danger of losing their money? Clearly upon FDA approval of DNDN there was a big short squeeze, and some shorts lost their money.
The shorts in MNKD who post or write articles have really some of the weakest jabs ever, given the Phase III data already made public by MNKD.
bergstromrobert138, if you consult a daily chart of MNKD, you will see technically MNKD is in a compressed triangle pattern, aka wedge, from August and November of 2013 to today. These things normally act like coiled springs when a decisive up or down price move is finally made. Today on the chart I drew for myself months ago, the top of the triangle is about 6.7, and the bottom of the triangle is about 5.4. I expect more bouncing around of the MNKD stock price within this narrowing triangle right up to the Advisory Committee meeting and then even up to the PDUFA decision. Once a decision is made, AdCom and/or PDUFA, I expect the price to zip much higher or much lower suddenly and decisively. That is what would be expected.
You mentioned how many shares you own, and I own considerably more than you named. This volatility does not bother me, because I see plenty of stocks that get into these compressed triangles (or wedges). This MNDK triangle trend is neither rising nor falling. That is even more obvious on a weekly chart. We are just waiting on a couple of binary events, and you can expect volatility higher and lower until those events happen. My expectation is for a price rise much higher, because I believe we will see approval of Afrezza. In the interim I expect volatility. These weekly options are a particular reason I think we see even more volatility.
drevil6406, please, help me out with this question I cannot rationalize in my head. The language as I read it in this latest POSAR SEC document still appears to me to limit Deerfield to a maximum number of common shares it can own, even now, in the aggregate is still 12 million shares. Correct? I think so. Deerfield has already converted one $40M tranche to 7.852 million shares. If the 12 million shares is valid still, Deerfield can only convert about 4.15 million more shares. I am trying to understand what Deerfield has the freedom to do with the rest of the convertible notes once the 12M share mark is reached. I don't think MNKD would want to keep servicing that debt for a long time. I have not read whether MNKD can payoff the debt on some accelerated schedule.
getaclueorgetglue, you need to go to the SEC POSAR filing on pages 6 and 7 to get the information I supplied for you above about the $80 million of the other note tranches. Is that dick and jane enough for you?
bbarra1, I agree 100% with your last paragraph. I think in your 2nd paragraph in the first sentence that uses 2nd CRL, it should be 1st CRL instead. Otherwise I agree with your overall analysis.
He was trying to get any palm readers who might hold MNKD stock to think about uncertainty.
The conclusion of that article convinced me Feuerstein asked his weekly palm reader to write an article. My question as I read the conclusion was how was this article on Seeking Alpha PRO first? I guess Feuerstein thought that might give the article some kind of fear credibility. The guy, Webb, went really strange when he mentioned Joseph Campbell.
From the half full SA article on CHK's Yahoo summary page this might help some understand the more appropriate production growth in 4Q13 vs. 4Q12.
"Adjusted for 2013's $4.4B in asset sales, total production in Q4 2013 increased approximately 10% year over year. This is good growth for a company the size of CHK."
This new set of IOS 7 icons and representations for things like bookmarks and things like that look kind of amateurish compared to Apple representations in the past. All I can guess is they save power and thus provide longer battery life.
It has been weeks since I saw Cramer say he would not buy MNKD during his lightning round. Did he recently reiterate his don't buy? It was not during his Monday show today that I saw.
pfg_01, I was playing no word game. I simply meant the insulin that Afrezza finally delivers to the blood stream is the monomer insulin of the same IUPAC insulin formula that a human pancreas delivers to the blood stream. To me when an insulin analog gets into the blood stream, if the active ingredient insulin does not have the identical IUPAC formula as pancreatic insulin, it is not real insulin or human insulin -- and it behaves differently in the body too. (Of course this is the problem Al Mann recognized and has solved.)
I will go along with you and call Afrezza an insulin analog in a strict definition, but upon dissolving Afrezza delivers in a strict definition real insulin to the blood stream that behaves exactly like insulin from a human pancreas. It should, because it is the identical IUPAC chemical formula as human pancreatic insulin.
You will need plenty of cash until then, because you are going to have to make several margin calls between now and April 2. After April 1 you won't need to make margin calls, because you will be out of cash and the margin clerk will cover your shorts at still higher prices -- you will be broke.
pfg_01, just a point of order. Afrezza is not an insulin analog. Afrezza delivers to the blood stream monomer insulin just as the human pancreas delivers monomer insulin to the blood stream. It is real insulin instead of an insulin analog. I do not understand the sentence containing "older style human insulins." I am not aware of a human insulin other than real insulin from a pancreas, or perhaps hexamer insulin that can be injected and slowly dissolves in the blood stream to release some difficult to control amount of monomer insulin over a long time period.